鼻咽癌的全球市場:預測(2022年～2028年)

全球上咽喉癌的市場規模在預測期間內預計將以約2.6％的年複合成長率擴大。由於過度吸煙和飲酒導致鼻咽癌患病率急劇上升，是推動該市場增長的主要因素。鼻咽癌的高患病率預計將增加對有效藥物和治療的需求，進一步推動市場增長。

本報告提供全球上咽喉癌市場相關調查，提供市場概要，以及各癌症類型，各診斷方法，不同治療，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

第3章 競爭情形

• 主要企業分析
  • 概要
  • 財務分析
  • SWOT分析
• 主要策略分析
• COVID-19對主要的市場參與企業帶來的影響

第4章 市場決策要素

• 促進因素
• 阻礙因素
• 機會

第5章 市場區隔

• 全球上咽喉癌市場，各癌症類型
  • 角化鱗狀細胞癌
  • 非角化鱗狀細胞癌
  • 未分化癌症
  • 其他(腺癌及腺先生囊胞癌症)
• 全球上咽喉癌市場，各診斷方法
  • 初期診斷
  • 先進的診斷
• 全球上咽喉癌市場，不同治療
  • 化療
  • 免疫療法
  • 放射治療
  • 標靶治療
  • 手術

第6章 地區分析

• 北美
• 歐洲
• 亞太地區
• 其他地區

第7章 企業簡介

• BioDiem Ltd.
• Biocon Ltd.
• Bristol-Myers Squibb Co.
• Cyclacel Pharmaceuticals, Inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd,
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• ONO Pharmaceutical Co., Ltd
• Pfizer Inc.
• Sanofi SA

Global Nasopharyngeal Cancer Market Size, Share & Trends Analysis Report By Cancer Type (Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma, and Others) By Diagnosis Method (Initial Diagnosis and Advanced Diagnosis) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others) Forecast, 2021-2027

The global market for nasopharyngeal cancer is projected to have a considerable CAGR of around 2.6% during the forecast period. The nasopharynx is the upper part of the throat (pharynx) that lies behind the nose. The nasopharynx cancer or nasopharyngeal carcinoma (NPC) results from abnormal growth of cells in the nasopharynx. The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc. The dramatic rise in the prevalence rate of nasopharyngeal cancer owing to the excessive consumption of tobacco and alcohol is the major factor driving the growth of the market. According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women. Also, there were 129,000 new cases of nasopharyngeal cancer in 2018 according to the same estimates. Similarly, according to the International Agency for Research on Cancer (IARC) 2018 report, it is estimated that about 50,455 new cases of nasopharyngeal cancer will occur from 2018 to 2040. Thus, the high prevalence rate of nasopharyngeal cancer will increase the demands for effective drugs and therapies that will further lead to market growth.

Moreover, the high cost of treatment, low awareness of cancer and an adverse side effect of treatment are the major restraint factors that are hindering the growth of the market. As per the National Center for Biotechnology Information, the cost of treatment of NPC ranges from $15,000 to $18,000. On other hand, the rapid adoption of technologies in healthcare premises, increasing awareness campaigns for nasopharyngeal cancer (NPC), and adoption of nasopharyngeal cancer diagnosis and treatment are expected to boost the market growth and will create lucrative opportunities during the forecast period.

Impact Of COVID-19 on Global Nasopharyngeal Cancer Market

The global market for nasopharyngeal cancer has experienced a positive impact due to the COVID-19 pandemic. As patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer, due to this the demand for diagnosis and treatments/therapies associated with this cancer were increased. This led to the growth of the market.

Segmental Outlook

The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy. Based on cancer type, the market is categorized into keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma, undifferentiated carcinomas, and other (adenocarcinoma and adenoid cystic carcinomas). Based on the diagnosis method, the market is bifurcated into initial diagnosis and advanced diagnosis. The Initial diagnosis is further classified into nasendoscopy, panendoscopy, and fine-needle aspiration/needle biopsy. Similarly, the advanced diagnosis is further classified into CT scan, PET scan, MRI scan, and Bone scan. Whereas, based on therapy, the market is divided into chemotherapy, immunotherapy, surgery, targeted therapy, and radiation therapy.

Global Nasopharyngeal Cancer Market Share by Therapy, 2020 (%)

Global Nasopharyngeal Cancer Market Share by Therapy

The Radiation Therapy Segment is Projected to Hold the Significant Market Share in Nasopharyngeal Cancer Market

Based on therapy, the radiation therapy segment is projected to grow at a significant CAGR during the forecast period. Radiation therapy is the most preferred and common therapy among all other therapies for the treatment of nasopharyngeal cancer. in radiation therapy, high-energy x-rays or particles are used to kill cancer cells or slow their rate of growth. Most of the time, radiation therapy is given along with chemotherapy to increase its effects in the treatment of NPC. This procedure is called chemoradiation. There are two types of radiation therapy for NPC are external beam radiation therapy (EBRT), and brachytherapy (internal radiation). Due to the increasing prevalence of nasopharyngeal cancer rates, the increase in the adoption of this therapy has been witnessed. Thus, owing to the above factors the segment is expected to show growth in the near future.

Regional Outlook

Geographically, the global Nasopharyngeal Cancer market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, North America is the fastest growing region during the forecast period. The factors that drive the growth of the market in the region include, the increasing cases of nasopharyngeal cancer owing to the high consumption of alcohol, tobacco, and cigarette. The development in the healthcare sectors and the adoption of advanced treatments and therapies for nasopharyngeal cancer is also propelling the growth of the market.

Global Nasopharyngeal Cancer Market Growth, by Region 2021-2027

Global Nasopharyngeal Cancer Market Growth, by Region

Asia-Pacific Dominates the global Nasopharyngeal Cancer Market

Geographically, Asia-Pacific dominated the market in 2020, and it is projected to further maintain its dominance in the global nasopharyngeal cancer market during the forecast period. In Asia-Pacific, nasopharyngeal cancer is the most common cancer. Especially in South Asia, where the prevalence rate of this cancer is high. According to the World Cancer Research in 2018, the five countries with the highest incidence of nasopharyngeal cancer in the world were China, Indonesia, Vietnam, India, and Malaysia. The increasing prevalence of nasopharyngeal cancer rates in South Asia is expected to drive market growth during the forecast period. Besides, the large customer base, the continuous increment in the economy, and healthcare facilities are the prominent factors for the growth of the market in the region.

Market Players Outlook

The key players in the global nasopharyngeal cancer market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are BioDiem Ltd, Biocon Limited, Bristol-Myers Squibb Co., Cyclacel Pharmaceuticals, Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, FDA approvals, and geographical expansions to generated more revenue and to remain competitive in the market. For instance, in September 2020, the US FDA had approved Toripalimab, as a potential treatment for nasopharyngeal carcinoma (NPC), being developed by Junshi Bioscience.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Nasopharyngeal Cancer market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Nasopharyngeal Cancer Industry
• Recovery Scenario of Global Nasopharyngeal Cancer Industry
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
• 3.2. Key Strategy Analysis
• 3.3. Impact of Covid on key players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Nasopharyngeal Cancer Market, By Cancer Type
  • 5.1.1. Keratinising Squamous Cell Carcinoma
  • 5.1.2. Non-Keratinising Squamous Cell Carcinoma
  • 5.1.3. Undifferentiated Carcinomas
  • 5.1.4. Other (Adenocarcinoma and Adenoid Cystic Carcinomas)
• 5.2. Global Nasopharyngeal Cancer Market, By Diagnosis Method
  • 5.2.1. Initial Diagnosis
    • 5.2.1.1. Nasendoscopy
    • 5.2.1.2. Panendoscopy
    • 5.2.1.3. Fine Needle Aspiration/Needle Biopsy
  • 5.2.2. Advanced Diagnosis
    • 5.2.2.1. CT Scan
    • 5.2.2.2. PET Scan
    • 5.2.2.3. MRI Scan
    • 5.2.2.4. Bone Scan
• 5.3. Global Nasopharyngeal Cancer Market, By Therapy
  • 5.3.1. Chemotherapy
  • 5.3.2. Immunotherapy
  • 5.3.3. Radiation Therapy
  • 5.3.4. Targeted Therapy
  • 5.3.5. Surgery

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Russia
  • 6.2.7. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korean
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World
  • 6.4.1. Latin America
  • 6.4.2. Middle East& Africa

7. Company Profiles

• 7.1. BioDiem Ltd.
• 7.2. Biocon Ltd.
• 7.3. Bristol-Myers Squibb Co.
• 7.4. Cyclacel Pharmaceuticals, Inc.
• 7.5. Eli Lilly and Co.
• 7.6. F. Hoffmann-La Roche Ltd,
• 7.7. GlaxoSmithKline Plc
• 7.8. Merck & Co., Inc.
• 7.9. Novartis AG
• 7.10. ONO Pharmaceutical Co., Ltd
• 7.11. Pfizer Inc.
• 7.12. Sanofi SA

LIST OF TABLES

• 1. GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($ MILLION)
• 2. GLOBAL KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 3. GLOBAL NON-KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 4. GLOBAL UNDIFFERENTIATED CARCINOMAS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 5. GLOBAL OTHER (ADENOCARCINOMA AND ADENOID CYSTIC CARCINOMAS) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 6. GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
• 7. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 8. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 9. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 10. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 11. GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
• 12. GLOBAL CHEMOTHERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 13. GLOBAL IMMUNOTHERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 14. GLOBAL RADIATION THERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 15. GLOBAL TARGETED THERAPY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 16. GLOBAL SURGERY IN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 17. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 18. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE,2020-2027 ($ MILLION)
• 19. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
• 20. NORTH AMERICAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
• 21. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 22. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE,2020-2027 ($ MILLION)
• 23. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2020-2027 ($ MILLION)
• 24. EUROPEAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
• 25. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 26. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($ MILLION)
• 27. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD,2020-2027 ($ MILLION)
• 28. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
• 29. ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027 ($ MILLION)
• 30. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 31. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($ MILLION)
• 32. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD,2020-2027 ($ MILLION)
• 33. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL NASOPHARYNGEAL CANCER MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL NASOPHARYNGEAL CANCER MARKET BY SEGMENT, 2020-2027 (% MILLION)

• 3. RECOVERY OF GLOBAL NASOPHARYNGEAL CANCER MARKET, 2020-2027 (%)
• 4. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BY CANCER TYPE,2020 VS 2027 (%)
• 5. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BYDIAGNOSIS METHOD,2020 VS 2027 (%)
• 6. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BY THERAPY,2020 VS 2027 (%)
• 7. GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 8. GLOBAL KERATINISING SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 9. GLOBAL NON-KERATINISING SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 10. GLOBAL UNDIFFERENTIATED CARCINOMAS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 11. GLOBAL OTHER (ADENOCARCINOMA AND ADENOID CYSTIC CARCINOMAS) MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 12. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 13. GLOBAL INITIAL DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 14. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER SHARE BY REGION, 2020-2027 ($ MILLION)
• 15. GLOBAL ADVANCED DIAGNOSIS FOR NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 16. GLOBAL CHEMOTHERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 17. GLOBAL IMMUNOTHERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 18. GLOBAL RADIATION THERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 19. GLOBAL TARGETED THERAPY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 20. GLOBAL SURGERY IN NASOPHARYNGEAL CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 21. US NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 22. CANADA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 23. UK NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 24. FRANCE NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 25. GERMANY NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 26. ITALY NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 27. SPAIN NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 28. REST OF EUROPE NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 29. INDIA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 30. CHINA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 31. JAPAN NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 32. SOUTH KOREA NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 33. REST OF ASIA-PACIFIC NASOPHARYNGEAL CANCER MARKET SIZE, 2020-2027 ($ MILLION)
• 34. REST OF THE WORLD NASOPHARYNGEAL CANCER MARKET SIZE, 2021-2027($ MILLION)